Author:
Berg Tobias,Knop Ann Søegaard,Jakobsen Erik Hugger
Abstract
Metastatic breast cancer claims the lives of 1,000 Danish women each year. Current guidelines are focused on the three major immunohistochemical subtypes in breast cancer. This review covers current Danish guidelines for the treatment of advanced breast cancer and highlights the potential future treatments for Danish patients.
Publisher
Danish Medical Association
Reference28 articles.
1. Jensen MB, Ejlertsen B, Mouridsen HT et al. Improvements in breast cancer survival between 1995 and 2012 in Denmark: the importance of earlier diagnosis and adjuvant treatment. Acta Oncol. 2016;55 Suppl 2:24-35. https://doi.org/10.3109/0284186X.2015.1128119
2. Pan H, Gray R, Braybrooke J et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836-46. doi: https://doi.org/10.1056/NEJMoa1701830
3. Deluche E, Antoine A, Bachelot T et al. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016. Eur J Cancer. 2020;129:60-70. doi: https://doi.org/10.1016/j.ejca.2020.01.016
4. DBCG. Systemisk behandling af brystkræft III - palliativ og systemisk behandling af metastaserende brystkræft (MBC), 2021. https://www.dmcg.dk/siteassets/kliniske-retningslinjer---skabeloner-og-vejledninger/kliniske-retningslinjer-opdelt-pa-dmcg/dbcg/dbcg_pall-syste-bh-mbc_v1.3_admgodk070722.pdf (1. dec 2022).
5. DBCG. Billeddiagnostik ved LABC, verificeret lokalrecidiv mistanke om fjernrecidiv og monitorering af metastatisk brystkræft, 2024. https://www.dmcg.dk/Kliniske-retningslinjer/kliniske-retningslinjer-opdelt-paa-dmcg/brystcancer/billeddiagnostik_ved_LABC/ (14. feb 2024).